HMS Networks commits to net-zero emissions – validated by Science-Based Targets HMS Networks AB has received official validation of its climate targets from the Science Based Targets initiative (SBTi) — a significant milestone in the company’s journey toward a sustainable future. This approval reinforces HMS’ commitment to reducing emissions in line with climate science and the goals of the Paris Agreement. HMS products help customers improve productivity and sustainability. Companies turn to HMS to enable communication for machines and devices — thereby reducing energy consumption and ser...
HMS Networks åtar sig att nå nettonollutsläpp – validerat av Science Based Targets HMS Networks AB har fått sina klimatmål officiellt validerade av Science Based Targets initiative (SBTi) — en betydande milstolpe i företagets hållbarhetsresa. Godkännandet stärker HMS engagemang i att minska utsläppen i linje med Parisavtalets mål. HMS produkter hjälper kunder att förbättra produktivitet och hållbarhet. Företag vänder sig till HMS för att möjliggöra kommunikation mellan industriella maskiner och enheter — vilket minskar energiförbrukning och serviceresor. Men HMS har också högt ställda mål ...
HMS Networks acquires Industrial Communications Business from Molex Industrial Solutions Business Unit HMS Networks’ growth journey continues with an acquisition by its Industrial Network Technology (INT) division. Today HMS entered into a binding agreement to acquire part of the Industrial Solutions Business Unit of Molex. Molex is a global electronics leader committed to transforming technology innovation with interconnect solutions for a wide range of industries. Molex has a presence in more than 38 countries and has over 50,000 employees. The acquisition consists of several strategic ...
HMS Networks förvärvar affärsenheten ”Industrial Communications” från Molex Industrial Solutions division HMS Networks fortsätter sin tillväxtresa genom ett strategiskt förvärv inom Industrial Network Technology-divisionen (INT). HMS har idag ingått ett bindande avtal om att förvärva delar av Molex division Industrial Solutions. Molex är en global ledande aktör inom elektroniktillverkning med fokus på att driva teknisk innovation genom anslutningslösningar för en mängd olika branscher. Koncernen har verksamhet i över 38 länder och mer än 50 000 anställda. Förvärvet omfattar flerta...
Nordic Semiconductor, leader in Bluetooth Low Energy (BLE), is entering a recovery cycle driven by the rebound in PC accessories and the launch of its nRF54 chip (2026e sales at +16%). But we think this momentum is already largely priced into what is a demanding valuation (relative-to-peer premium of ~40%). This exposes the group to the risk of de-rating in the event of disappointment. Moreover, we think long-term growth in BLE and operating leverage are probably overestimated (we are 18% below ...
Leader du Bluetooth Low Energy (BLE), Nordic Semiconductor aborde un cycle de reprise tiré par le rebond des accessoires PC et le lancement de sa puce nRF54 (CA 26e à +16%). Cette dynamique nous semble néanmoins déjà bien reflétée dans une valorisation exigeante (prime de ~40% vs comparables). Cela expose le groupe à un risque de derating en cas de déception, alors que nous pensons que la croissance LT du BLE et le levier opérationnel sont probablement surestimés (nous sommes 18% < au css sur l’...
A director at Nordic Semiconductor ASA bought 4,000 shares at 133.600NOK and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
Three Directors at Swedish Orphan Biovitrum AB sold after exercising options/sold 208,150 shares at between 324.800SEK and 324.856SEK. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary ...
Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS subtypes, including in those with recurrent disease Discussion of the first ever international, randomized, multicentre, double-blind, placebo-controlled phase 2 dose finding trial of Vonjo® (pacritinib) in adult patients with VEXAS syndrome WALTHAM, Mass., Oct. 25...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.